Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study
- PMID: 24952415
- PMCID: PMC4074853
- DOI: 10.1186/1471-2172-15-26
Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study
Abstract
Background: Patients with antibody deficiencies depend on the presence of a variety of antibody specificities in intravenous immunoglobulin (IVIG) to ensure continued protection against pathogens. Few studies have examined levels of antibodies to specific pathogens in IVIG preparations and little is known about the specific antibody levels in patients under regular IVIG treatment. The current study determined the range of antibodies to tetanus, diphtheria, measles and varicella in IVIG products and the levels of these antibodies in patients undergoing IVIG treatment.
Methods: We selected 21 patients with primary antibody deficiencies who were receiving regular therapy with IVIG. Over a period of one year, we collected four blood samples from each patient (every 3 months), immediately before immunoglobulin infusion. We also collected samples from the IVIG preparation the patients received the month prior to blood collection. Antibody levels to tetanus, diphtheria, measles and varicella virus were measured in plasma and IVIG samples. Total IgG levels were determined in plasma samples.
Results: Antibody levels to tetanus, diphtheria, varicella virus and measles showed considerable variation in different IVIG lots, but they were similar when compared between commercial preparations. All patients presented with protective levels of antibodies specific for tetanus, measles and varicella. Some patients had suboptimal diphtheria antibody levels. There was a significant correlation between serum and IVIG antibodies to all pathogens, except tetanus. There was a significant correlation between diphtheria and varicella antibodies with total IgG levels, but there was no significant correlation with antibodies to tetanus or measles.
Conclusions: The study confirmed the variation in specific antibody levels between batches of the same brand of IVIG. Apart from the most common infections to which these patients are susceptible, health care providers must be aware of other vaccine preventable diseases, which still exist globally.
Figures


Similar articles
-
Protective antibody concentrations in primary immunodeficiency following infusion with 5% or 10% intravenous immunoglobulin.Allergy Asthma Proc. 2024 Nov 1;45(6):414-420. doi: 10.2500/aap.2024.45.240033. Epub 2024 Sep 13. Allergy Asthma Proc. 2024. PMID: 39271296 Clinical Trial.
-
Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment.Allergol Immunopathol (Madr). 2017 Jan-Feb;45(1):55-62. doi: 10.1016/j.aller.2016.04.014. Epub 2016 Jul 29. Allergol Immunopathol (Madr). 2017. PMID: 27480789
-
Diphtheria, tetanus, and varicella immunity in health care workers in neonatal units.Am J Infect Control. 2008 Mar;36(2):142-7. doi: 10.1016/j.ajic.2007.04.283. Am J Infect Control. 2008. PMID: 18313517
-
Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies.Immunotherapy. 2024;16(13):895-905. doi: 10.1080/1750743X.2024.2382074. Epub 2024 Sep 26. Immunotherapy. 2024. PMID: 39323406 Free PMC article. Review.
-
Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs.Front Immunol. 2023 Mar 28;14:1166821. doi: 10.3389/fimmu.2023.1166821. eCollection 2023. Front Immunol. 2023. PMID: 37063852 Free PMC article. Review.
Cited by
-
Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy.J Exp Clin Cancer Res. 2019 Sep 18;38(1):408. doi: 10.1186/s13046-019-1410-x. J Exp Clin Cancer Res. 2019. PMID: 31533779 Free PMC article.
-
PROTECTIVE LEVELS OF VARICELLA-ZOSTER ANTIBODY DID NOT EFFECTIVELY PREVENT CHICKENPOX IN AN X-LINKED AGAMMAGLOBULINEMIA PATIENT.Rev Inst Med Trop Sao Paulo. 2015 Sep-Oct;57(5):455-7. doi: 10.1590/S0036-46652015000500017. Rev Inst Med Trop Sao Paulo. 2015. PMID: 26603238 Free PMC article.
-
Severe Tick-Borne Encephalitis (TBE) in a Patient with X-Linked Agammaglobulinemia; Treatment with TBE Virus IgG Positive Plasma, Clinical Outcome and T Cell Responses.J Clin Immunol. 2024 Apr 27;44(5):116. doi: 10.1007/s10875-024-01718-5. J Clin Immunol. 2024. PMID: 38676861 Free PMC article.
-
Measles neutralising antibody levels in patients receiving intravenous immunoglobulin treatment - a sub-analysis of a randomized, cross-over bioequivalence trial.PLoS One. 2025 Feb 7;20(2):e0316926. doi: 10.1371/journal.pone.0316926. eCollection 2025. PLoS One. 2025. PMID: 39919133 Free PMC article. Clinical Trial.
-
Characterization of antibodies in human immunoglobulin products from different regions worldwide.Int J Infect Dis. 2021 Mar;104:610-616. doi: 10.1016/j.ijid.2021.01.034. Epub 2021 Jan 29. Int J Infect Dis. 2021. PMID: 33524620 Free PMC article.
References
-
- Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011;37(5):396–404. - PubMed
-
- Gelfang EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006;6(4):592–599. - PubMed
-
- Lejtenyi D, Mazer B. Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations. J Allergy Clin Immunol. 2008;121(1):254–255. - PubMed
-
- Mikolajczyk MG, Concepcion NF, Wang T, Frazier D, Golding B, Frasch CE, Scott DE. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenza type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol. 2004;11(6):1158–1164. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical